Shouhei Tomori1, Yukiko Nishi1, Sawako Nakachi1, Sachie Uchibori1, Sakiko Kitamura1, Taeko Hanashiro1, Natsuki Shimabukuro1, Keita Tamaki1, Iori Tedokon1, Kazuho Morichika1, Kennosuke Karube2, Takuya Fukushima3, Satoko Morishima1, Hiroaki Masuzaki1 (1.Second Department of Internal Medicine, Ryukyus Univ., Okinawa, Japan, 2.Department of Pathology and Cell Biology, Ryukyus Univ., Okinawa, Japan, 3.Laboratory of Hematoimmunology, Univ. of the Ryukyus, Okinawa, Japan)
Session information
Oral Session
Oral Session 3-8B ATL: Treatment
Sun. Oct 14, 2018 9:40 AM - 10:40 AM No.8 (Osaka International Convention Center, 10F 1002)
Chair: Kenji Ishitsuka (Department of Hematologuy and Rheumatology Kagoshima Universdity Hospital, Japan)
Shigeo Fuji1,2, Takuhiro Yamaguchi3, Yoshitaka Inoue4, Atae Utsunomiya5, Yukiyoshi Moriuchi6, Satsuki Owatari7, Takashi Miyagi8, Yasushi Sawayama9, Eiichi Ohtsuka10, Shinichiro Yoshida11, Takahiro Fukuda2 (1.Hematology, Osaka International Cancer Institute, Osaka, Japan, 2.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, 3.Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan, 4.Hematology, Kumamoto University Hospital, Kumamoto, Japan, 5.Hematology, Imamura General Hospital, Kagoshima, Japan, 6.Hematology, Sasebo City General Hospital, Sasebo, Japan, 7.Hematology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan, 8.Hematology, Heart-Life Hospital, Okinawa, Japan, 9.Hematology, Nagasaki University Hospital, Nagasaki, Japan, 10.Hematology, Oita Prefectural Hospital, Oita, Japan, 11.Hematology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan)
Ki-Ryang Koh1, Dai Momose1, Masahiro Manabe1, Yasuyoshi Sugano1, Masayuki Hino2 (1.Hematol., Osaka General Hospital of West Japan Railway Company, Japan, 2.Hematol., Osaka City University, Osaka, Japan)
Masahito Tokunaga1, Nobuaki Nakano1, Tomohisa Tabuchi1, Jun Odawara1, Ayumu Kubota1, Mayumi Tokunaga1, Kentaro Yonekura2, Takayoshi Miyazono1, Torahiko Makino1, Shogo Takeuchi1, Yoshifusa Takatsuka1, Yoshikiyo Ito1, Atae Utsunomiya1 (1.Department of Hematology, Imamura General Hospital, Kagoshima, Japan, 2.Department of Dermatology, Imamura General Hospital, Kagoshima, Japan)
Yuma Sakamoto1, Takashi Ishida2,3, Ayako Masaki1, Takayuki Murase1, Kentaro Yonekura4, Yukie Tashiro5, Masahito Tokunaga6, Atae Utsunomiya6, Asahi Ito3, Shigeru Kusumoto3, Shinsuke Iida3, Ryuzo Ueda7, Hiroshi Inagaki1 (1.Dept. Clin. Pathol., Nagoya City Univ., Sch. Med., 2.Hematol & Oncol, Iwate Medical Univ., Sch. Med., 3.Dept. Hematol., Nagoya City Univ., Sch. Med., 4.Dept. Dermatol., Imamura General Hosp., 5.Dept. Pathol., Imamura General Hosp., 6.Dept. Hematol., Imamura General Hosp., 7.Dept. Tumor Immunol, Aichi Medical Univ., Sch. Med.)
Kosuke Toyoda1,2, Jun-Ichiro Yasunaga2, Ilseung Choi3, Youko Suehiro3,4, Naokuni Uike5, Jun Okamura6, Masao Matsuoka1,2 (1.Virus Control, IFLMS, Kyoto University, Kyoto, Japan, 2.Hematology, Rheumatology and Infectious Diseases, Kumamoto University, Kumamoto, Japan, 3.Hematology, National Kyushu Cancer Center, Fukuoka, Japan, 4.Cell Therapy, National Kyushu Cancer Center, Fukuoka, Japan, 5.Palliative Care, Saga-ken Medical Center Koseikan, Saga, Japan, 6.Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka, Japan)